# Bvlaser

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bvlaser

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Total disclosed funding: $15M
- Latest round: Series C (Dec 15, 2025)
- Investors on record: 8

## About

Based in Suzhou, China and founded in 2022, Suzhou Baifu Laser Technology Co., Ltd., trading as Bvlaser, is a medical beauty equipment developer that focuses on the research and development, production, and sales of medical beauty optoelectronic equipment. The founder of the company, Yangchun Jia graduated from the University of Salamanca, Spain. The company has obtained more than 100 intellectual property certificates. In December 2025, Bvlaser raised a series C funding led by new investor TigerYeah Capital, with participation from new investors Hubei Science Technology Investment Group, Ennovation Ventures, Leader Venture Capital, returning investors NLVC, MED-FINE Capital and other investors.
The company mainly provides medical beauty optoelectronic equipment. The equipment includes 100-picosecond laser, alexandrite long pulse laser, erbium laser, thulium laser, and Q-switched laser. The treatment areas of the equipment include skin treatment, cosmetic surgery, etc. The products can be used in dermatology, plastic surgery, rehabilitation medicine, and other fields. The products have been exported to more than 70 regions including North America, South America, Europe, etc.
The company’s revenue is generated by providing medical beauty optoelectronic equipment such as 100-picosecond laser and alexandrite long pulse laser.
The series C financing will inject strong momentum into the company's global expansion strategy, brand value enhancement, and core technology iteration, driving greater breakthroughs for domestically produced medical aesthetic laser equipment in the global high-end market.

## Funding rounds

- Series C, Dec 15, 2025 — NLVC, Hubei Science Technology Investment Group, MED-FINE Capital, TigerYeah Capital, Ennovation Ventures, Leader Venture Capital
- Series B, Nov 23, 2024 — MED-FINE Capital
- Series B, Jun 27, 2024 — Beijing New Aerotropolis Fund Management
- Series A, Jul 7, 2022, $15M — NLVC, YuanBio Venture

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A, Series C
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Beijing New Aerotropolis Fund Management (https://capitalatlas.ai/funds/beijing-new-aerotropolis-fund-management) — Series B
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series B, Series C
- Hubei Science Technology Investment Group — Series C
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series C
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series C
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series C